NCT07473726
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07473726
Title A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Shanghai Henlius Biotech
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS

Facility Status City State Zip Country Details
Macquarie University NOT_YET_RECRUITING North Ryde New South Wales 2109 Australia Details
GenesisCare St.Leonards NOT_YET_RECRUITING Saint Leonards New South Wales 2065 Australia Details
Peninsula and South Eastern Haematology and Oncology Group NOT_YET_RECRUITING Frankston Victoria 3199 Australia Details
Zhujiang Hospital of Southern Medical University NOT_YET_RECRUITING Guangzhou Guangdong 510280 China Details
Sun Yat-Sen University Cancer Center RECRUITING Guangzhou Guangzhou 716099 China Details
Shanghai General Hospital RECRUITING Hongkou Shanghai Municipality 200080 China Details
Shanxi Provincial Cancer Hospital NOT_YET_RECRUITING Taiyuan Shanxi 030000 China Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field